Aeglea was founded in 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. Aeglea's pipeline of engineered human enzymes includes AEB1102, which we expect will enter into clinical trials in both hyperargininemia and cancer. In addition, three additional drug candidates are in pre-clinical development: AEB4104, which degrades homocystine, is being evaluated as a potential treatment for the inborn error of metabolism homocystinuria; AEB3103, which degrades cysteine/cysteine, is being evaluated for its ability to increase oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies; and AEB2109, which degrades methionine, is being evaluated for the treatment of solid tumors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/23/15 | $44,000,000 | Series B |
Ally Bridge Group Cowen Investments Jennison Associates Novartis Venture Funds OrbiMed Advisors RA Capital Rock Springs Capital UT Horizon Fund Venrock | undisclosed |
